EGFR and non-small cell lung carcinoma: However, our results showed that EGFR-TKI plus angiogenesis inhibitor therapy in NSCLC with non-baseline brain metastases prolonged PFS significantly compared with EGFR-TKI monotherapy (baseline brain metastasis: HR: 0.71, 95%CI: 0.52~0.97, P=0.03; non-baseline brain metastasis: HR: 0.63, 95%CI: 0.51~0.77, P<0.0001).